Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday

Climb Bio (NASDAQ:CLYM) is anticipated to release its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect Climb Bio to post earnings of ($0.20) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 7:00 AM ET.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06). On average, analysts expect Climb Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Climb Bio Stock Performance

Climb Bio stock opened at $7.13 on Tuesday. The stock has a market capitalization of $340.60 million, a price-to-earnings ratio of -8.01 and a beta of -0.26. Climb Bio has a 52-week low of $1.05 and a 52-week high of $8.04. The stock’s 50 day moving average price is $5.59 and its two-hundred day moving average price is $3.54.

Institutional Trading of Climb Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in Climb Bio during the first quarter worth $27,000. Qube Research & Technologies Ltd bought a new position in shares of Climb Bio in the second quarter valued at $43,000. Virtu Financial LLC acquired a new position in shares of Climb Bio during the fourth quarter valued at about $43,000. Blair William & Co. IL bought a new stake in shares of Climb Bio during the fourth quarter worth about $44,000. Finally, Marshall Wace LLP bought a new stake in shares of Climb Bio during the second quarter worth about $46,000. Institutional investors own 69.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Robert W. Baird boosted their target price on shares of Climb Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. HC Wainwright lifted their price target on shares of Climb Bio from $11.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Wedbush initiated coverage on shares of Climb Bio in a report on Thursday, March 5th. They set an “outperform” rating and a $12.00 price objective on the stock. Piper Sandler initiated coverage on Climb Bio in a research note on Friday, February 13th. They issued an “overweight” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Climb Bio presently has an average rating of “Moderate Buy” and a consensus price target of $11.40.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.